In summary, this paper highlights a previously unrecognized therapeutic vulnerability of neuroblastomas with MYCN amplification to small molecule inhibitors of G9a, As MYCN is also a known driver of several other cancers, this work underlines the need for future work on these cancers with current inhibitors, and the development of next generation G9a inhibitors. Here, MYCN is linked to neuroblastoma.